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In 2005 a newly discovered T helper cell subset that secreted interleukin (IL)-17 became
the center of attention in immunology. Initial studies painted Th17 cells as the culprit for
destruction in many different autoimmune and auto-inﬂammatory diseases. Subsequently,
the discovery of patients with primary immunodeﬁciencies in the IL -17 pathway taught
us thatTh17 cells have a critical role in defense against certain fungal and bacterial infec-
tions. Moreover, the paradoxical exacerbation of Crohn’s disease in the clinical trials of a
Secukinumab (AIN457), a fully human neutralizing antibody to IL -17A, has cast into doubt
a universal pro-inﬂammatory and harmful role forTh17 cells. Evidence now suggests that
depending on the environmentTh17 cells can alter their differentiation program, ultimately
giving rise to either protective or pro-inﬂammatory cells. In this review we will summarize
the evidence from patients with immunodeﬁciencies, autoimmune, or auto-inﬂammatory
diseases that teaches us how the pro-inﬂammatory versus protective function ofTh17 cells
varies within the context of different human diseases.
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type 1 diabetes, secukinumab
INTRODUCTION
In rare cases,a mutation in an essential gene can disrupt immune
homeostasis, leading to clinical immunodeﬁciency. More com-
monly,whenindividualswithageneticpredispositionareexposed
to environmental triggers, a failure of immune homeostasis can
lead to autoimmunity. In this review, we will discuss how par-
allel studies of immunodeﬁciencies and autoimmune diseases
have advanced our knowledge of a CD4+ T cell lineage ﬁrst
characterized by production of IL-17A,Th17 cells.
Th17 cells were identiﬁed in 2005 (Harrington et al., 2005;
Langrish et al., 2005; Park et al., 2005) and, as for other CD4+
T cell lineages, their development, is controlled by a combina-
tion of cytokines which initiate a program of transcription fac-
tor expression and epigenetic re-modeling (van der Gast et al.,
2011). In humans, the cytokines which instruct Th17 cell lin-
eage development likely include IL-6, IL-21, IL-23, and IL-1β
(Acosta-Rodriguez et al., 2007a; Chen et al., 2007; Evans et al.,
2007; Wilson et al., 2007; Liu and Rohowsky-Kochan, 2008), with
a potential synergistic role for TGF-β (Manel et al., 2008; Volpe
et al., 2008; Yang et al., 2008a) via its ability to suppress Th1 cell
lineage commitment (Santarlasci et al., 2009). Cytokine-driven
activation of the signal transducer and activator of transcription
(STAT) 3 pathway is an essential step in Th17 cell differentiation
(Holland et al.,2007;Yang et al.,2007; Ma et al.,2008),ultimately
leading to expression of their lineage-deﬁning transcription fac-
tor: retinoid orphan receptor (ROR)C2 (Acosta-Rodriguez et al.,
2007a; Annunziato et al., 2007; Wilson et al., 2007; Manel et al.,
2008; Crome et al., 2009). Although the IL-17 cytokine family
includes six members (Kolls and Linden, 2004), Th17 cells are
thought to only produce IL-17A and IL-17F,which are 55% iden-
tical (Kolls and Linden, 2004). IL-17A can combine with IL-17F
to form a heterodimer and both can form homodimers (Wright
et al.,2007).
Th17 cells have many phenotypic characteristics that distin-
guish them from other Th cell lineages. In addition to IL-17A and
IL-17F, Th17 cells secrete other signature cytokines including IL-
21 and IL-22 (Bending et al., 2011). They have also been reported
to produce IFN-γ (Annunziato et al., 2007), IL-4 (Cosmi et al.,
2010), IL-10 (McGeachy et al., 2007), IL-9 (Beriou et al., 2010),
IL-26, CXCL8, and CCL20 (Boniface et al., 2008). They are poor
producers of IL-2, which may result in their poor proliferative
potential in vitro (Santarlasci et al.,2012). They constitutively co-
expressCCR4andCCR6,butnotCXCR3(Acosta-Rodriguezetal.,
2007b), and are derived from CD161+ precursors (Cosmi et al.,
2008). The effects of Th17 cells on other cells have recently been
highlighted in many reviews (Annunziato and Romagnani, 2011;
Gaffen, 2011; Gaffen et al., 2011; Ghoreschi et al., 2011; Milner,
2011; Pappu et al., 2011; Wilke et al., 2011).
Th17 cells initially developed a reputation as a destructive
element in several diseases including multiple sclerosis (MS),
rheumatoidarthritis(RA),psoriasis,andinﬂammatoryboweldis-
ease (IBD). In animal models this reputation,came from evidence
that the lack of IL-17-producing cells ameliorates experimental
autoimmune encephalitis (EAE) and collagen induced arthri-
tis (CIA; Cua et al., 2003). In humans, the reputation was due
to correlative data documenting an increase in IL-17-producing
cells, particularly at sites of tissue inﬂammation (Wilke et al.,
2011). However, these original conclusions were over-simpliﬁed
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and as discussed below in some diseases Th17 cells clearly have a
protective role.
THE ROLE OF Th17 CELLS IN PRIMARY
IMMUNODEFICIENCIES
Much of what we know about human Th17 cells comes from
the study of a rare primary immunodeﬁciency called Hyper-
immunoglobulin E (Job’s, syndrome). This disease is caused by
mutations in STAT3 (Holland et al.,2007) but the underlying cel-
lular basis for the characteristic phenotype of severe pneumonias,
mucocutaneous candidiasis, and Staphylococcus aureus abscesses
(Buckley et al.,1972;Grimbacher et al.,1999) remained unknown
until several groups found that these patients lack Th17 cells in
their peripheral blood (de Beaucoudrey et al., 2008; Ma et al.,
2008; Milner et al., 2008; Renner et al., 2008). In addition, naïve
Th cells from Job’s syndrome patients have low levels of RORC2
expression and cannot be differentiated into Th17 cells in vitro
(de Beaucoudrey et al., 2008; Ma et al., 2008; Milner et al., 2008;
Renner et al., 2008).
OnecomplicationwheninterpretingdatafromJob’ssyndrome
patients is that STAT3 is activated downstream of other cytokines,
makingitdifﬁculttoattributeaclinicalphenotypetoonepathway.
Recently, other immunodeﬁciencies have been described which
involve more speciﬁc defects in the IL-17 pathway. For example,
twopatientswithchronicmucocutaneouscandidiasis(CMC)dis-
ease,characterizedbychronicorpersistentinfectionwithCandida
albicans and S. aureus, were found to have an IL-17RA autosomal
recessive deﬁciency or an IL-17F autosomal dominant deﬁciency
(Puel et al., 2011). In addition, patients with a deﬁciency in
the intracellular adaptor molecule CARD9, which is essential for
dectin-1 signaling,also suffer from systemic Candidiasis infection
(Glocker et al.,2009) and have low numbers of Th17 cells in their
peripheral blood.
Together, these data have led to the hypothesis that in humans
Th17 cells have an essential role in protective immunity the spe-
ciﬁc pathogens C. albicans and S. aureus. In accordance with this
conclusion, Sallusto et al. have characterized different subsets of
human Th17 cells that can be differentiated in vitro with antigen
speciﬁc stimulation by C. albicans and S. aureus (Zielinski et al.,
2012).
Th17 cells have an intriguing close developmental link with
FOXP3+CD4+ regulatoryTcells(Tregs).FOXP3andRORC2can
directly interact via a DNA-independent mechanism, and dur-
ing Th17 cell development FOXP3 is transiently expressed (Zhou
etal.,2008).Moreover,uponactivationfullydifferentiatedhuman
Th17 cells preferentially express FOXP3 in comparison to Th1
cells (McMurchy and Levings, unpublished data). Indeed there is
increasing evidence for the existence of cells that co-express IL-17
and FOXP3 (Ayyoub et al., 2009; Beriou et al., 2009; Miyara et al.,
2009;Voo et al., 2009; Kryczek et al., 2011;Ye et al.,2011).
Immune dysregulation, polyendocrinopathy, enteropathy X-
linked syndrome (IPEX) is a triad of autoimmune syndromes
includingenteropathy,type1diabetes,andhyper-IgE(McMurchy
etal.,2010),resultingfrommutationsinFOXP3.Thecellularbasis
for this disease has been attributed to Treg dysfunction (Bacchetta
et al., 2006; D’Hennezel et al., 2009), but recently Bacchetta et al.
investigated whether part of the cellular defect in IPEX patients
may not only relate to Treg dysfunction, but also to changes
in Th17 cells. Indeed IPEX patients possessed an increased fre-
quency of cells with a surface proﬁle characteristic of Th17 cells
(CD4+CCR6+CD161+), expressing RORC2, and producing IL-
17 (Passerini et al., 2011). Interestingly, in patients with point
mutations that do not abrogate FOXP3 expression, there was an
increased frequency of FOXP3+ cells within the CD161+ Th17
cell gate. These data suggest that dysfunctional Tregs may prefer-
entially differentiate into Th17 cells and that an expansion of this
subset may underlie some of the clinical phenotype of IPEX. An
alternative interpretation is that the Th17 cells in IPEX patients
are highly activated and that in this case FOXP3 expression is
a consequence of T cell activation and not Treg lineage commit-
ment(Ziegler,2006).Regardless,inthisimmunodeﬁciencythereis
strong correlative evidence that Th17 cells may have a detrimental
pro-inﬂammatory effect.
EVIDENCE FOR THE PRO-INFLAMMATORY ROLE OF Th17 IN
HUMAN AUTOIMMUNITY
The ﬁrst recognition of the importance of Th17 cells came from
studies of EAE. The notion of EAE as a Th1-mediated disease was
challenged when mice deﬁcient in the p40 subunit of IL-12 were
foundtoberesistanttoEAEwhereasmicedeﬁcientinthep35sub-
unitwereactuallymoresusceptibletodisease(Becheretal.,2002).
Cua et al. (2003) solved this paradox by using genetically deﬁcient
mice to show that IL-23p19 and IL-12p40,but not IL-12p35,were
essential for EAE development. IL-23, which shares the IL-12p40
subunitwithIL-12,wassubsequentlyfoundtostabilizeTh17cells,
and these cells were found to be the main contributing factor in
EAE (Langrish et al., 2005). Subsequently, a correlation between
Th17 cells and human autoimmunity was sought. Below we dis-
cuss the evidence for a pro-inﬂammatory role in autoimmunity
and describe attempts to target this axis therapeutically.
Psoriasisisanauto-inﬂammatoryskindiseasecharacterizedby
recurrent demarcated red and scaly skin plaques. These plaques
include inﬁltrating T cells (mainly Th cells) and dendritic cells in
the dermis as well as cytotoxic T cells and neutrophil in the epi-
dermis (Lowes et al., 2007). The resulting inﬂammatory process
results in rapid keratinocyte proliferation, abnormal keratinocyte
differentiation, and angiogenesis (Lowes et al., 2007). Initially,
increased levels of IFN-γ, TNF-α, and IL-12 in the serum and
lesions of psoriasis patients labeled this as a Th1-mediated disease
(DiCesareetal.,2009).However,RORC,IL-1β,IL-6,andIL-23are
alsoincreasedinpsoriaticskinlesions(DiCesareetal.,2009)lead-
ing to the possibility that Th17 and Th1 act in synergy to produce
psoriatic inﬂammation.
Th17 cells are thought to be recruited to the skin by expres-
sionof CCL20,theligandforCCR6,thenlocallystabilizedbyIL-1
and IL-23. Since both IL-17 and IFN-γ cause keratinocytes and




IL-12 and IL-23 (Ustekinumab) have been approved for clinical
use in psoriasis. Since IL-17 can act synergistically with TNF-α to
inducekeratinocytestoexpressinﬂammatoryproteins(Chiricozzi
etal.,2011),itispossiblethatanti-TNF-αactsinpartbyinhibiting
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Th17cell-driveninﬂammation.TargetingIL-17alonewithSecuk-
inumab (AIN457) or Ixekizumab, both fully human neutralizing
antibodies to IL-17A, is also effective in psoriasis (Hueber et al.,
2010; Leonardi et al., 2012), conﬁrming that this is likely a major
pathogenic cytokine in this skin disease. Since Th17 cells are not
thesoleproducersof IL-17[otherpossiblesourcesof thiscytokine
in psoriatic plaques include γδ T cells (Cai et al., 2011), mast cells
(Lin et al.,2011),neutrophils (Lin et al.,2011),and Tregs (Boven-
schenetal.,2011)],whetherornotTh17cellsarethemajorsource
of this cytokine in skin remains to be determined.
Another disease with strong links to Th17 cells is RA,a chronic
autoimmune disease that leads to joint destruction. T cells inﬁl-
trating the synovial ﬂuid of RA patients produce high amounts
of IL-17A, IL-1β, and IL-6 (Cascao et al., 2010), especially during
early disease and pre-treatment (Chabaud et al.,1999;Ziolkowska
et al., 2000; Hwang and Kim, 2005; Leipe et al., 2010). Notably,
the levels of IL-17 in the synovium correlate with joint damage,
whereas those of IFN-γ correlate with protection (Kirkham et al.,
2006).RecentevidencesupportsaroleforIL-17FaswellasIL-17A
in RA, with the two related cytokines acting in synergy to induce
other pro-inﬂammatory cytokines and chemokines in synovio-
cytes, myeloid cells, and synovial ﬁbroblasts (Lundy et al., 2007;
Tran et al., 2007; Hot and Miossec, 2011; van Hamburg et al.,
2011). Hence, analogous to the process in psoriasis, a positive
pro-inﬂammatory feedback loop encourages more Th17 differ-
entiation and maintenance in the joint (reviewed in Sarkar and
Fox, 2010). Direct clinical evidence for the role of IL-17 in RA




Multiple sclerosis is a neurological disease that results from
auto-inﬂammatory damage to the myelin sheaths surrounding
nerves in the brain and spinal cord. This disease has historically
beenassociatedwiththediscoveryof Th17cellssince,asdiscussed
above, they have a major pathogenic role in EAE (Bettelli et al.,
2008; Dong, 2008; Dubin and Kolls, 2008; Weaver and Hatton,
2009). MS patients have increased IL-17 mRNA in their blood as
well as cerebrospinal ﬂuid (Matusevicius et al.,1999),and expres-
sion of miRNA326 in their peripheral blood mononuclear cells
promotes Th17 cell differentiation and correlates with disease
severity (Du et al., 2009). Blood-brain barrier endothelial cells
layers are more permeable to in vitro polarized Th17 cells, espe-
cially if the monolayer is pre-treated with IL-17 or IL-22 (Kebir
et al., 2007). These data led to the hypothesis that in MS Th17
cells weaken the blood-brain barrier and enable the migration of
immunecellsintothenormallyimmuneprivilegedsiteswithinthe
centralnervoussystem.If thisisthecase,thenTh17cellsmayhave
more of a facilitative than directly pathogenic role in the nervous
system, distinct from their clear role in the positive feedback loop
of inﬂammationinpsoriasisandRA.Recruitmenthasbegunfora
phase II clinical trials of Secukinumab in patients with relapsing-
remitting MS. This trial will provide signiﬁcant insight into the
question of whether IL-17 blockade in MS can induce a clinically
relevant protective function.
Type1diabetes(T1D)ischaracterizedbyautoimmunedestruc-
tion of pancreatic islet cells resulting in the loss of insulin
production. Murine studies have yielded conﬂicting results on
the role of Th17 in the NOD mouse model of T1D (Vukkadapu
et al., 2005; Jain et al., 2008; Emamaullee et al., 2009; van den
Brandt et al., 2010; Lee et al., 2011; Liu et al., 2011; Joseph et al.,
2012),includingapotentialabilitytoconvertintoTh1cellsinvivo
(Bending et al.,2009; Martin-Orozco et al.,2009). However,more
recentdatasuggestsomeofthisapparentplasticitycouldberelated
to the study of in vitro polarized Th17 cells, which are not suf-
ﬁciently stabilized at the epigenetic level (Bending et al., 2011;
Cohenetal.,2011).PatientswithT1D,haveanincreaseincirculat-
ing IL-17-producing cells (Honkanen et al., 2010; Marwaha et al.,
2010; Hughson et al., 2011), including FOXP3 expressing Th17
cells (Marwaha et al., 2010), monocytes that secrete Th17 polar-
izing cytokines (Bradshaw et al., 2009), and islet-antigen speciﬁc
Th17cells(Arif etal.,2011).Thereisalsoevidencethatpancreatic
lymph nodes from T1D patients have an increase in Th17 cells
(Ferraro et al., 2011) and that islets from T1D patients, who died
close to diagnosis, express IL-17A, RORC, and IL-22 (Arif et al.,
2011). Mechanistically IL-17 enhances IL-1β, IFN-γ, and TNF-
α-induced apoptosis in human islets (Arif et al., 2011). We have
also found that signiﬁcantly elevated levels of CD8+IL-17+ cells
are detectable in the peripheral blood of a large subset of patients
with T1D at disease onset (Marwaha et al., 2010). In the context
of mounting correlative evidence that IL-17-producing cells may
be pathogenic in the early stages of T1D onset, clinical trials to
test the effects of therapy with agents such as Secukinumab or
Ustekinumab are warranted.
A PROTECTIVE ROLE FOR Th17 IN THE GUT
The success of Ustekinumab,a human IL-12/23 monoclonal anti-
body, in patients with moderate to severe Crohn’s disease held
promise for the targeting of the IL-17 pathway to modulate this
disease (Sandborn et al., 2008). However, the paradoxical exacer-
bation of Crohn’s disease in the clinical trial of a Secukinumab,
castintodoubtthepro-inﬂammatoryroleof Th17cellsinthegut.
Whilst IL-17 cell-producing cells are found in high numbers in
inﬂamedmucosainCrohn’sdiseaseandUlcerativecolitispatients,
more recent data demonstrate that characterization on the basis
of IL-17 alone is insufﬁcient to classify these cells as pathogenic.
Asdescribedabove,Th17canco-secreteIFN-γ (Annunziatoetal.,
2007; Lee et al., 2009; Cosmi et al., 2011; Hirota et al., 2011)o r
co-express FOXP3 (Ayyoub et al.,2009;Beriou et al.,2009;Miyara
et al., 2009; Voo et al., 2009; Kryczek et al., 2011; Ye et al., 2011),
indicating the existence of multiple subsets of Th17 cells with
functional specialization (Figure 1).
Inretrospect,datafrommousemodelsofcolitisheededawarn-
ing as to the protective role for Th17 cells in Crohn’s disease. In
the dextran sulfate sodium (DSS)-induced colitis model, admin-
istration of a neutralizing IL-17A antibody (Ogawa et al., 2004),
deletion of IL-17A (Yang et al., 2008b), or of IL-22 (Zenewicz
et al., 2008) all resulted in a worsening of the colitis. In con-
trast, IL-17F-deﬁcient (Yang et al., 2008b) and IL-21-deﬁcient
mice (Fina et al., 2008) were protected against DSS induced
colitis. These data suggest there are non-redundant roles of IL-
17A versus F, and that, at least in the gut, IL-21 rather than
IL-17A or IL-22 may be a primary Th17-derived pathogenic
cytokine.
How could Th17-derived cytokines exert a protective func-
tionalroleintheintestine?First,IL-17Aimprovesbarrierfunction
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FIGURE 1 |The protective and pathogenic functions ofTh17 cells.
Depending on the local cytokine environment, different subsets ofTh17
cells arise and mediate distinct effector function. In the presence of IL -23,
Th17 cells seem to be pro-inﬂammatory and can either make IFN-γ
themselves or work in concert withTh1 cells to drive a positive feedback
pathway of tissue damage such as that seen in psoriasis or RA. In Crohn’s
disease,Th17 cells can differentiate in the gut into protective or pathogenic
Th17 cells. In the presence ofTGF-β and IL -21,Th17 are re-programmed into




improves barrier function by inducing epithelial cell proliferation
(Brand et al., 2006) and enhancing goblet cell restoration and
mucus production (Sugimoto et al., 2008). Also, a novel suppres-
siveTh17subsetdubbedregulatoryTh17(rTh17)cellshasrecently
beendescribed.WhenEspluguesetal.(2011)usedaCD3-antibody
strategy to induce mucosal tolerance, Th17 cells were recruited
to the gut but then re-programmed into suppressive, FOXP3-
negative, rTh17 cells. The function of rTh17 cells depends on
IL-10,TGF-β,and CTLA-4,and does not occur in CCR6-deﬁcient
mice where Th17 are not recruited to the gut. The latter data indi-
cate that the mucosal immunity micro-environment is critical for
the development of rTh17 cells.
CONCLUSION
Different ﬂavors of Th17 differentiation, ranging from highly
pro-inﬂammatory to suppressive, result from different cytokine
micro-environments in various diseases. Th17 cells can no longer
be identiﬁed solely on the production of IL-17A since the com-
bination of co-secreted cytokines is key to deﬁning their effector
function. Moreover,IL-17 is not only produced by Th17 cells,and
undercertainconditionsγδTcells(Starketal.,2005),CD8+Tcells
(Shinetal.,1998;Heetal.,2006),Tfollicularhelpercells(Cuaand
Tato, 2010), Lymphoid Tissue induced (LTi) cells (Cupedo et al.,
2009), and NKT cells (Michel et al., 2007; Lee et al., 2008; Rachit-
skaya et al., 2008), can all secrete IL-17. We must therefore start
to redeﬁne the partial role that Th17 cells play in IL-17-guided
immune response. An additional consideration is their potential
forplasticityandco-secretionofcytokinesthatdeﬁneotherThcell
lineages(e.g.,IFN-γ),althoughthisismorelikelyatransientrather
than permanent change based on epigenetic analysis (Bending
et al.,2011;Cohen et al.,2011). In summary,the notion that Th17
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